October 2017 update

October was mostly spent at drug policy conferences. These were helpful platforms for meeting in person with collaborators, and for better understanding the organizations involved in US drug policy & how they relate to one another.

All-drug decriminalization now seems to be most leveraged & neglected path towards psychedelic liberalization in the US (see DPA's recent report (a) for more on all-drug decrim). We may write more about this in the coming weeks.

Looking forward, we plan to spend November:

• Running further polling to more granularly understand public support for drug liberalization strategies
• Learning more about the mechanics & process of ballot initiatives
• Learning more about how possible FDA approval of MDMA-assisted psychotherapy for PTSD (a) and psilocybin-assisted psychotherapy for depression (a) would interact with the impact of all-drug decriminalization efforts